Celcuity is a clinical-stage biotechnology company developing integrated companion diagnostic and therapeutic strategies using its proprietary functional cellular analysis platform. The CELsignia platform analyzes live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies. The company also offers the Gedatolisib drug candidate, a small molecule dual inhibitor that selectively targets all Class 1 isoforms of PI3K and mammalian target of rapamycin (mTOR).